Dr Alieu Amara
Alieu was employed as a postdoctoral research assistant and went on to assume the role of deputy laboratory manager at the Bioanalytical Facility. His responsibilities included developing and validating highly sensitive LC-MS/MS assays for measurement of drugs in body fluids as well as liaising with sponsors to coordinate trials for drug exposure in different populations such as pregnant women, children and in infectious diseases like HIV, TB, Hepatitis C. He worked closely on the LONGEVITY project (AGILE trial), developing methods for identifying different drugs to help treat and prevent COVID-19.
Justin Chiong
Justin took up a role as Programme Manager at University of Liverpool's Infection Pharmacology Group to support CELT by coordinating clincal trials out of the Bioanalytical Facility for the LONGEVITY project.
Dr Laura Dickinson
Laura undertook a role as a Pharmacometrician with research interests focusing on anti-infective pharmacology, particularly therapeutics used to treat HIV and tuberculosis. She has previously worked on population pharmacokinetic (PK) model development using concentration-time data collected as part of clinical studies from various populations including HIV-infected adults, pregnant women and their infants. Population PK is a methodology defining a mathematical description of drug PK for a population, estimating variability in parameters and identifying sources of that variability. Laura has worked on on the analysis of PK data emerging from the AGILE platform which aims to rapidly identify and evaluate drugs to treat and prevent COVID-19.